Actionable news
All posts from Actionable news
Actionable news in NVO: NOVO-NORDISK A/S,

UPDATE 2-Novo Nordisk raises forecasts despite continued U.S. pressure

* Second-quarter earnings (EBIT) beat forecasts

* Lifts 2017 outlook in local currencies, lowers in crowns

* Says prices in core business seen falling in 2018

* Says obesity drug growth "very promising"

* Shares jump more than 6 percent (Adds management comments, obesity drugs background, shares)

By Stine Jacobsen and Jacob Gronholt-Pedersen

COPENHAGEN, Aug 9 (Reuters) - Novo Nordisk, the world's leading maker of diabetes drugs, reported better than expected profit on Wednesday driven by new diabetes and obesity drugs though it said sale prices would remain under pressure in the United States.

The Danish drugmaker shocked markets in 2016 by cutting its long-term operating profit forecasts twice on the back of price pressures in its main U.S. market, sending its shares down more than 40 percent last year.

The company said its second-quarter operating profit came in at 13.4 billion crowns ($2.1 billion), above an average estimate of 12.7 billion in a Reuters poll, and raised its forecasts for both sales and operating profit this year.

"Although the formulary negotiations in the USA reflect the tough competitive environment, we remain confident that our long-term financial growth targets are achievable," Chief Executive Lars Fruergaard Jorgensen said in a statement.

Novo Nordisk's shares jumped more than 6 percent and were 5.1 percent higher at 1015 GMT, boosted by the second-quarter earnings and...